LEGN Earnings Prediction
The chart below shows how LEGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LEGN sees a +2.87% change in stock price 10 days leading up to the earnings, and a -0.99% change 10 days following the report. On the earnings day itself, the stock moves by -0.04%. This data can give you a slight idea of what to expect for the next quarter's release.
LEGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
160.21M
66.86%
-14.11%
Gross Margin
65.38%
19.48%
-10.38%
Operating Margin
-43.92%
-54.43%
95.20%
Net Margin
-78.23%
20.74%
701.54%
EPS
-0.34
-100.00%
580.00%
No Data Available
LEGN Earnings Analysis
Legend Biotech Corporation American Depositary Shares Corporation (LEGN.O) Earnings Conference Call
Positive
CARVYKTI Cell Growth: CARVYKTI cells delivered quarter-over-quarter growth of 53% and year-over-year growth of 87%.
CARVYKTI Sales Surge: Net trade sales of CARVYKTI were approximately $286 million, reflecting an 87.6% increase year-over-year and a 53.2% increase quarter-over-quarter.
Survival Improvement in Myeloma: CARVYKTI reduced the risk of death by 45% compared to standard therapies after a three-year follow-up period, marking a significant milestone in overall survival for multiple myeloma patients.
CARVYKTI Production Expansion: The company has expanded its ability to produce CARVYKTI for patients in Europe, receiving approval for commercial production at the Obelisc facility in Ghent, Belgium.
Sufficient Capital Reserves: As of September 30th, Legend Biotech had $1.2 billion in cash and equivalents, providing sufficient capital to fund operations into 2026.
Negative
Net Loss Increase: 1. Increased Net Loss: The net loss for Q3 2024 was $125 million, a significant increase from a net loss of $62 million in Q3 2023, indicating worsening financial performance year-over-year.
Foreign Exchange Impact: 2. Foreign Exchange Losses: The company incurred unrealized foreign exchange losses of $63 million in Q3 2024, compared to a gain of $16 million in the same period last year, highlighting increased financial volatility.
Increased Selling Expenses: 3. Rising Selling and Distribution Expenses: Selling and distribution expenses rose to $44 million in Q3 2024, up from $21 million in Q3 2023, reflecting increased costs associated with commercial activities for CARVYKTI.
Administrative Expense Increase: 4. Higher Administrative Expenses: Administrative expenses increased to $35 million in Q3 2024, compared to $28 million in Q3 2023, driven by the expansion of administrative functions and infrastructure.
Collaboration Cost Rise: 5. Collaboration Cost Increase: Collaboration cost of revenue for Q3 2024 was $52 million, up from $43 million in Q3 2023, indicating rising costs associated with collaboration agreements.
LEGN FAQs
How does LEGN typically perform around its earnings report dates?
Is Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LEGN Earning Call Sentiment
Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LEGN.O
-3.08%Positive
The earnings call reveals financial concerns, with a net loss of $125 million and significant foreign exchange losses. Despite strong CARVYKTI sales, competitive pressures and operational risks are high. The lack of a shareholder return plan and management's vague responses in the Q&A section further contribute to uncertainty. The absence of quantitative guidance and unclear FDA regulations exacerbate the negative sentiment, pointing to a likely negative stock price movement in the short term.
